AN2 Therapeutics Inc. (ANTX)
NASDAQ: ANTX
· Real-Time Price · USD
1.22
-0.02 (-1.61%)
At close: May 02, 2025, 3:59 PM
1.22
0.41%
After-hours: May 02, 2025, 04:05 PM EDT
Company Description
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases.
It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease.
The company was incorporated in 2017 and is headquartered in Menlo Park, California.
AN2 Therapeutics Inc.
| Country | United States |
| IPO Date | Mar 25, 2022 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 22 |
| CEO | Eric E. Easom |
Contact Details
Address: 1800 El Camino Real Menlo Park, California United States | |
| Website | https://www.an2therapeutics.com |
Stock Details
| Ticker Symbol | ANTX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001880438 |
| CUSIP Number | 037326105 |
| ISIN Number | US0373261058 |
| Employer ID | 82-0606654 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Eric E. Easom | Co-Founder, Chief Executive Officer, President & Chairman of the Board |
| Joshua Eizen J.D. | Chief Legal Officer, Chief Operating Officer & Corporate Secretary |
| Lucy O. Day CPA | Chief Financial Officer, Principal Financial Officer & Principal Accounting Officer |
| Dr. George Harrison Talbot FACP, M.D. | Co-Founder & Senior Clinical Advisor |
| Dr. Michael R. K. Alley Ph.D. | Co-Founder, Senior Vice President of Research Fellow & Head of Biology |
| Dr. Sanjay Chanda Ph.D. | Chief Development Officer |
| Dr. Stephen David Prior Ph.D. | Chief Strategy Officer |
| Joseph S. Zakrzewski | Co-Founder & Independent Chairman of the Board |
| Vince Hernandez | Senior Vice President of Research & Head of Chemistry |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 01, 2025 | 8-K | Current Report |
| Apr 11, 2025 | 4 | Filing |
| Apr 11, 2025 | 4 | Filing |
| Apr 11, 2025 | 4 | Filing |
| Apr 11, 2025 | ARS | Filing |
| Apr 10, 2025 | DEFA14A | Filing |
| Apr 10, 2025 | DEF 14A | Filing |
| Mar 25, 2025 | S-8 | Filing |
| Mar 25, 2025 | 10-K | Annual Report |
| Mar 25, 2025 | 8-K | Current Report |